Results 141 to 150 of about 45,696 (262)

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection

Microbiology Spectrum
KPC-producing Klebsiella pneumoniae infections are a rising global health threat. The factors driving blaKPC mutations during treatment and their contribution to infection persistence remain unclear.
Feng Yang, Weiwei Yang, Jinghao Zhang, Chengkang Tang, Li Ding, Siquan Shen, Yanhao Zhou, Hongyu Zhao, Jiaojiao Zhou, Fupin Hu   +9 more
doaj   +1 more source

**In vitro** antibacterial activity of the ceftazidime-avibactam (NXL104) combination against **Pseudomonas aeruginosa** clinical isolates

, 2012
: The beta-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa ...
Goossens, Herman, Coleman, Kenneth, Girard, Anne-Marie, Claudon, Monique, Black, Michael T., Levasseur, Premavathy, Miossec, Christine   +6 more
core  

Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive Klebsiella pneumoniae MBL+, NDM+

Mateusz Szymański,1,2 Małgorzata M Skiba,2 Małgorzata Piasecka,2 Alina Olender3 1Human Anatomy Department, Medical University, Lublin, Poland; 2Intensive Care Unit, Stefan Cardinal Wyszyński District Specialist Hospital ...
Szymański M, Olender A, Skiba MM, Piasecka M   +3 more
core  

Will Ceftazidime-Avibactam Replace Polymyxins in Asia?

Clinical Infectious Diseases, 2021
Sock Hoon, Tan, Narendran, Koomanan, Shimin Jasmine, Chung, Andrea Lay-Hoon, Kwa   +3 more
openaire   +2 more sources

Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis

Cureus
There is limited real-world data from India examining the treatment characteristics, safety, and efficacy of ceftazidime-avibactam against Gram-negative organisms especially multidrug-resistant pathogens including carbapenem-resistant Enterobacterales ...
S. Todi, Prachee Sathe, R. V, Subramanian Swaminathan, Deepak Talwar, P. Prayag, Polati Vishnu Rao, Kirti C Sabnis, Shweta Kamat, A. Mane, Harish Thanusubramanian   +10 more
semanticscholar   +1 more source

Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing Klebsiella pneumoniae bloodstream infection: a retrospective cohort study

JAC-Antimicrobial Resistance
Background Bloodstream infections (BSIs) caused by KPC-producing Klebsiella pneumoniae (KPC-Kp) are still associated with high mortality, and the game-changing drug ceftazidime/avibactam has shown suboptimal pharmacokinetics in some clinical settings ...
A. Oliva, L. Volpicelli, A. Gigante, M. Di Nillo, S. Trapani, A. Viscido, F. Sacco, C. Mastroianni   +7 more
semanticscholar   +1 more source

Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae

, 2018
Background The efficacy of ceftazidime-Avibactam-a cephalosporin-β-lactamase inhibitor combination with in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE)-compared with colistin remains ...
Doi Y., Paterson D.L., van Duin D., Cober E., Richter S.S., Lok J.J., Earley M., Bonomo R.A., Fowler V.G., Kaye K.S., Perez F., Salata R.A., Kalayjian R.C., Watkins R.R., Evans S.   +14 more
core   +1 more source

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting

Journal of Global Antimicrobial Resistance
BACKGROUND: Ceftazidime-avibactam (CZA) represents a novel therapeutic approach for combating infections caused by multidrug-resistant Gram-negative bacteria. With the rise of antimicrobial resistance posing a significant challenge in hospital settings, this study aims to evaluate the utilization of CZA in hospitals and its subsequent outcomes. METHODS:
Shobana Selvaganesan, Dorairajan Suresh Kumar, Rithik Dharan   +2 more
openaire   +2 more sources

A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria

Journal of Antimicrobial Chemotherapy
Background Carbapenem-resistant Gram-negative bacteria (CR-GNB) develop resistance to many antimicrobials. To effectively manage infections caused by these organisms, novel agents and/or combinations of antimicrobials are required.
G. M. Assefa, J. Roberts, A. T. Aslan, S. A. Mohammed, F. Sime   +4 more
semanticscholar   +1 more source

Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.

Indian Journal of Medical Microbiology
PURPOSE The choice of antibiotics for treatment of Carbapenem-Resistant Enterobacterales (CRE) is increasing becoming limited due to co-expression of Metallo-beta-lactamases (MBL) along with other carbapenemases in these isolates.
R. Kalaivani, A. Kali, R. Surendran, T. Sujaritha, C. Ganesh Babu   +4 more
semanticscholar   +1 more source